Correction to: Leukemia (2016) 30, 1701–1707; doi:10.1038/leu.2016.148
Following the publication of this article the authors noted that the IPSS risk assignment was incorrectly listed in the second paragraph of the Results section. The correct proportions of patients with intermediate-2-risk or high-risk MF should be 40 and 60%, respectively, not 60 and 40% as listed in the original.
The authors wish to apologize for any inconvenience caused.
Additional information
The online version of the original article can be found at 10.1038/leu.2016.148
Rights and permissions
About this article
Cite this article
Harrison, C., Vannucchi, A., Kiladjian, JJ. et al. Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 31, 775 (2017). https://doi.org/10.1038/leu.2016.323
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.323
This article is cited by
-
Primäre Myelofibrose
Die Onkologie (2023)
-
Therapiestrategien bei myeloproliferativen Neoplasien
Die Onkologie (2022)
-
MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations
International Journal of Hematology (2021)
-
Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions
International Journal of Hematology (2020)
-
Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice
International Journal of Hematology (2019)